Search clinical trials for: CD64 antigens

Total 284 results

Radboud University Medical Center
Bill and Melinda Gates Foundation

Completed

Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis (BMGF1)

Malaria

Netherlands
T.C. ORDU ÜNİVERSİTESİ

Completed

Blood Types and Erectile Dysfunction

Erectile Dysfunction
Pfizer

Completed

Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216

Meningococcal Meninigitis, Serogroup C

Austria, Germany
University of Medicine and Dentistry of New Jersey
Yale University

Completed

Exploring Massage Benefits for Arthritis of the Knee (EMBARK)

Osteoarthritis of the Knee

United States
FDA Office of Orphan Products Development

Completed

Keratinocyte Growth Factor to Prevent Acute GVHD

Graft-vs-Host Disease

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

HIV Infections

United States
GlaxoSmithKline

Terminated

Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer

Neoplasms, Breast

Belgium, United Kingdom, United States, Germany, Russian Federation, Italy
Seagen Inc.
Genentech, Inc.

Terminated

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States, France, Spain, Belgium, Australia, Germany, Poland, Italy, Czech Republic, Hungary
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Nanjing Medical University

Completed

Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B (PEG-Tα1)

Hepatitis B, Chronic

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Nanjing Medical University

Unknown

Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B (PEG-Tα1)

Hepatitis B, Chronic

China
French National Agency for Research on AIDS and...
Gilead Sciences; Roche Pharma AG

Completed

Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients (HB01EMVIPEG)

HIV Infections | Hepatitis B

France
Seagen Inc.

Completed

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

Acute Myeloid Leukemia

United States
Seagen Inc.
Genentech, Inc.

Completed

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States
National Institute of Allergy and Infectious Diseases...

Completed

Leprosy Skin Test Antigens Trial

Leprosy

Nepal, United States
Seagen Inc.

Terminated

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

Lymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, Hodgkin

United States
Seagen Inc.
Genentech, Inc.

Completed

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Neoplasms | Lymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, Hodgkin | Carcinomas

United States
Seagen Inc.

Completed

Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma

Anaplastic Large-Cell Lymphoma

United States
Seagen Inc.

Completed

A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma

Lymphoma, Non-Hodgkin | Carcinoma, Renal Cell

United States
Seagen Inc.
Genentech, Inc.

Completed

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

Non-Hodgkin Lymphoma

United States
Seagen Inc.
Genentech, Inc.

Completed

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

Multiple Myeloma

United States
Seagen Inc.
Genentech, Inc.

Completed

A Safety Study in Patients With Chronic Lymphocytic Leukemia

Leukemia, Lymphocytic, Chronic

United States
Seagen Inc.

Completed

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

Lymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, Hodgkin

United States
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Disease, Hodgkin

United States, Canada
Seagen Inc.

Completed

A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myeloproliferative Disorders | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Lymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, Hodgkin

United States, Germany
Seagen Inc.
Genentech, Inc.

Completed

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Multiple Myeloma

United States
National Institute of Allergy and Infectious Diseases...

Completed

Leprosy Skin Test Antigens Phase 1

Leprosy
University of Southern California

Completed

Novel Adjuvants for Peptide-Based Melanoma Vaccines

Melanoma

United States
Life Technologies Corporation

Completed

Clinical Protocol SeCore, uTYPE and 3500 Dx System

Human Leukocyte Antigens (HLA)
Yale University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Isocyanate Antigens and T Cells That Cause Asthma

Lung Diseases | Asthma
Seagen Inc.

Terminated

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly

Poliomyelitis

Philippines
University of Florida
American Brain Tumor Association

Withdrawn

Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens (PERFORMANCE)

Glioblastoma
University of Oxford

Completed

A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1

Plasmodium Falciparum Malaria

United Kingdom
GlaxoSmithKline

Completed

Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients

Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)

Singapore, Korea, Republic of
Northwestern University

Terminated

An In-vitro Standardization of B Cell Elispot Assays

Transplant Sensitization | Panel Reactive Antibody | Sensitization to HLA Antigens

United States
University of California, San Francisco
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Histoblood Group Antigens as a Risk Factor of Asthma

Lung Diseases | Asthma

United States
University Hospital Tuebingen
German Research Foundation

Completed

Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens

Malignant Melanoma

Germany
Tuberculosis Clinical Diagnostics Research Consortium
University of Cape Town

Unknown

Feasibility of a Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in South Africa

Tuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Miliary

South Africa
University of Oxford

Completed

A Study of AdCh63 ME-TRAP Alone and With MVA ME-TRAP

Malaria

United Kingdom
Victor J Marder, M.D.
Baxter Healthcare Corporation

Unknown

Personalized Prediction of Tolerance and Immunogenicity in Hemophilia (PPTIH)

Hemophilia A

United States
Roll International Corporation

Unknown

Open-label Extension Study of the Effects of Pomegranate Extract on Rising PSA After Primary Therapy for Prostate Cancer

Prostate Cancer

United States
Children's Hospital Medical Center, Cincinnati
United States Department of Defense

Completed

Susceptibility of Human Volunteers With Different Histo-Blood With Different Histo-Blood Group Antigens to Norovirus

Healthy Adults

United States
Tuberculosis Clinical Diagnostics Research Consortium
Makerere University

Unknown

Feasibility of a Lateral Flow Urine Lipoarabinomannan (LAM) Test for Diagnosis of Tuberculosis

Tuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Miliary

Uganda
Jules Bordet Institute

Unknown

Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia (ASCI)

Effects of Immunotherapy | Acute Myelogenous Leukemia | Myeloid Leukemia in Remission

Belgium
St Stephens Aids Trust

Terminated

Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens

HIV Infections

United Kingdom
Seagen Inc.

Completed

Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer

Prostatic Neoplasms

United States
Seagen Inc.

Completed

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome (MDS)

United States
Hadassah Medical Organization

Withdrawn

Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host

Neoplasm Metastasis | Hematological Malignancy

Israel

Search clinical trials for: CD64 antigens

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations